Skip to main content
Clinical Trials/NCT03982602
NCT03982602
Completed
Early Phase 1

Safety and Feasibility of Ketogenic Diet for Traumatic Brain Injury Study Protocol

University of Missouri-Columbia1 site in 1 country15 target enrollmentJuly 4, 2019

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Traumatic Brain Injury
Sponsor
University of Missouri-Columbia
Enrollment
15
Locations
1
Primary Endpoint
Development of Ketosis in blood
Status
Completed
Last Updated
last year

Overview

Brief Summary

Traumatic Brain Injury is a major health concern in United States. There is a un-met need to develop new therapeutic options for faster neuron recovery without causing significant side effects. The role of ketones in neuronal recovery has been studied and has been found to be useful in decreasing size of contusion. The present study aims to study the safety and feasibility profile of ketogenic diet.

Detailed Description

Traumatic Brain Injury (TBI) is a major health concern for United States contributing nearly one-third of injury-related deaths in United States. The Centers for Disease Control and Prevention (CDC) estimates that 1.7 million people in the United States sustain a TBI each year. It is responsible for significant disabilities and the total cost of productivity loss was estimated to be $76.5 billion in the United States in 2004. Several animal models have demonstrated the effectiveness of ketones in brain injury to decrease the size of contusion, improving cortical ATP levels, reduced brain edema and cellular apoptosis. Ketones have been shown to be effective in neuromodulation in animal models. Evaluation of carbohydrate free diet has been done in traumatic brain injury patients and it was noted to not cause fluctuations in blood glucose. There is a need for safety and feasibility study of ketogenic diet in traumatic brain injury patients and to understand the effectiveness in neuromodulation in humans. The present study focuses on identifying the safety and feasibility of KD in traumatic brain injury patients. This pilot project data will be utilized to design future randomized clinical trials. Based on the safety data, further trials will be conducted to evaluate the effectiveness of KD in traumatic brain injury patients and its effectiveness in controlling elevated intracranial pressure. It will open the avenue for consideration of new treatment option for intracranial pressure management and functional recovery. From a nutrition perspective, Ketogenic diet might become the standard of care for this patient population.

Registry
clinicaltrials.gov
Start Date
July 4, 2019
End Date
April 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Niraj Arora

Assistant Professor

University of Missouri-Columbia

Eligibility Criteria

Inclusion Criteria

  • Severe Traumatic Brain Injury
  • GCS\<= 8 with severe head injury
  • Age more than 18years

Exclusion Criteria

  • Diabetic Ketoacidosis
  • Unstable metabolic condition (persistent hyponatremia, hypernatremia, hypoglycemia, hypocalcemia, acidosis)
  • Cardiorespiratory or hemodynamic instability
  • Coagulopathy
  • Pancreatitis
  • Liver Failure
  • Severe hyperlipidemia
  • Inability to tolerate enteral feeds including ileus
  • Known Fatty acid oxidation disorder or pyruvate carboxylase deficiency
  • Any terminally ill patient with poor brain stem reflexes and mortality within 24h of admission.

Outcomes

Primary Outcomes

Development of Ketosis in blood

Time Frame: Baseline, till patient on KD ( maximum 1month)

Serum beta-hydroxybutyrate will be done alternate day to assess the level of ketosis in blood.

Excretion of Ketones in Urine

Time Frame: Baseline, till patient on KD (maximum 1 month)

Urine Ketones will be measured alternate day to assess the level of ketosis

Effect of Ketogenic Diet on Intracranial Pressure

Time Frame: Baseline, till patient on KD (maximim 1 month)

Intracranial Pressure will be measured hourly and it will be trended daily.

Secondary Outcomes

  • Evaluate subjects for muscle wasting(Baseline, till patient on Kd (Maximum 1month))
  • Evaluate subjects with gastro-intestinal adverse effects(Baseline, till patient on KD (Maximum 1month))
  • Evaluate change in the neurological exam(Baseline, before discharge from ICU)

Study Sites (1)

Loading locations...

Similar Trials